Skip to main content
. 2017 Jun 30;32(1):102–110. doi: 10.1038/leu.2017.179

Table 3. Relationship between genetic abnormalities and patient survival for intensively treated patients.

  Myeloma IX n=511
Myeloma XI n=598
Combined n=1109
Heterogeneity
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value P-value
(a) Progression-free survival
 t(4;14) 1.96 (1.49–2.59) 1.80 × 10−6 2.03 (1.56–2.64) 2.18 × 10−7 2.00 (1.65–2.42) 1.85 × 10−12 0.88
 t(14;16) 1.60 (0.96–2.69) 0.0729 2.03 (1.19–3.47) 0.0099 1.80 (1.23–2.60) 0.0021 0.54
 t(14;20) 0.96 (0.46–2.03) 0.9192 0.64 (0.09–4.54) 0.6524 0.91 (0.45–1.84) 0.7987 0.70
 Adverse translocations 1.81 (1.42–2.31) 1.79 × 10−6 2.09 (1.62–2.68) 8.88 × 10−9 1.94 (1.63–2.31) 1.07 × 10−13 0.42
 Del(17p) 1.81 (1.30–2.51) 0.0004 1.81 (1.29–2.52) 0.0005 1.81 (1.43–2.28) 7.25 × 10−7 1.00
 Gain(1q) 1.48 (1.22–1.80) 7.44 × 10−5 1.65 (1.31–2.07) 2.03 × 10−5 1.55 (1.34–1.80) 7.59 × 10−9 0.49
 Del(1p32) 1.05 (0.76–1.47) 0.7556 1.48 (1.04–2.09) 0.0286 1.23 (0.97–1.57) 0.0833 0.17
 ISS II 1.34 (1.01–1.77) 0.0409 1.48 (1.11–1.99) 0.0085 1.40 (1.15–1.72) 0.0009 0.61
 ISS III 1.43 (1.07–1.91) 0.0168 2.20 (1.61–3.01) 7.88 × 10−7 1.74 (1.40–2.16) 3.11 × 10−7 0.04
 1 Adverse lesion 1.50 (1.21–1.85) 0.0002 1.49 (1.15–1.93) 0.0024 1.50 (1.27–1.76) 1.36 × 10−6 0.99
 ‘Double hit’ >1 adverse lesion 2.31 (1.75–3.05) 3.67 × 10−14 3.00 (2.24–4.02) 2.17 × 10−13 2.61 (2.13–3.20) 1.07 × 10−20 0.21
 Intermediate risk-ISS 1.47 (1.16–1.86) 0.0015 1.87 (1.45–2.41) 1.45 × 10−6 1.64 (1.38–1.95) 2.10 × 10−8 0.17
 ‘Double hit’-ISS 2.78 (1.96–3.95) 9.85 × 10−9 3.42 (2.47–4.75) 1.92 × 10−13 3.11 (2.45–3.95) 1.59 × 10−20 0.40
  Myeloma IX n=511
Myeloma XI n=598
Combined n=1109
Heterogeneity
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value P-value
(b) OS
 t(4;14) 1.74 (1.26–2.41) 0.0008 2.09 (1.41–3.07) 0.0002 1.87 (1.46–2.40) 7.62 × 10−7 0.49
 t(14;16) 1.51 (0.79–2.84) 0.2059 2.31 (1.13–4.73) 0.0218 1.82 (1.13–2.92) 0.01359 0.38
 t(14;20) 1.44 (0.59–3.49) 0.4181 1.91 (0.26–13.70) 0.5219 1.51 (0.67–3.39) 0.3169 0.80
 Adverse translocations 1.74 (1.30–2.33) 0.0002 2.30 (1.60–3.31) 6.99 × 10−6 1.94 (1.55–2.43) 9.91 × 10−9 0.24
 Del(17p) 2.31 (1.61–3.31) 5.87 × 10−6 3.19 (2.10–4.85) 5.74 × 10−8 2.65 (2.01–3.48) 3.04 × 10−12 0.25
 Gain(1q) 1.79 (1.40–2.27) 2.33 × 10−6 1.72 (1.22–2.43) 0.0020 1.77 (1.45–2.15) 1.65 × 10−8 0.86
 Del(1p32) 1.84 (1.28–2.64) 0.0010 1.99 (1.25–3.18) 0.0037 1.89 (1.42–2.52) 1.23 × 10−5 0.78
 ISS II 1.96 (1.32–2.90) 0.0008 1.88 (1.14–3.11) 0.0140 1.92 (1.41–2.63) 3.27 × 10−5 0.90
 ISS III 2.56 (1.72–3.81) 3.59 × 10−6 3.22 (1.94–5.35) 6.56 × 10−6 2.79 (2.04–3.81) 1.30 × 10−10 0.49
 1 Adverse lesion 1.73 (1.32–2.26) 6.91 × 10−5 1.62 (1.08–2.44) 0.0207 1.69 (1.35–2.12) 4.30 × 10−6 0.79
 ‘Double hit’ >1 Adverse lesion 2.84 (2.05–3.94) 3.70 × 10−10 3.88 (2.55–5.92) 2.98 × 10−10 3.19 (2.47–4.14) 1.23 × 10−18 0.25
 Intermediate risk-ISS 2.36 (1.71–3.25) 1.44 × 10−7 2.26 (1.49–3.43) 0.0001 2.32 (1.80–3.00) 7.15 × 10−11 0.87
 ‘Double hit’-ISS 4.51 (2.97–6.83) 1.26 × 10−12 5.18 (3.24–8.27) 5.78 × 10−12 4.79 (3.51–6.54) 5.10 × 10−23 0.66

Abbreviations: CI, confidence interval; HR, hazard ratio; ISS, International Staging System; OS, overall survival.